[(1R,2S,5S,13S,14R,17R,18S,21S,26S,28S)-1,5,14,18,22,22,26-heptamethyl-7-sulfooxy-27-oxaheptacyclo[15.13.0.02,14.05,13.06,11.018,28.021,26]triaconta-6,8,10-trien-10-yl] hydrogen sulfate

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: [(1R,2S,5S,13S,14R,17R,18S,21S,26S,28S)-1,5,14,18,22,22,26-heptamethyl-7-sulfooxy-27-oxaheptacyclo[15.13.0.02,14.05,13.06,11.018,28.021,26]triaconta-6,8,10-trien-10-yl] hydrogen sulfate
• 化学式: C₃₆H₅₄O₉S₂
• 分子量: 694.9
• InChiKey: XXJQNRPPCJSVDF-HNFVNZPHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.7
• 重原子数：
  47
• 可旋转键数：
  4
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  153
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• MITOTIC KINESIN Eg5 INHIBITING ANTICANCER AGENTS
  申请人：THE CLEVELAND CLINIC FOUNDATION

  公开号：US20150352114A1

  公开（公告）日：2015-12-10

  A method of treating glioblastoma multiforme (GBM) in a subject in need thereof including administering to the subject a therapeutically effective amount of an Eg5 inhibitor.
• [EN] MITOTIC KINESIN Eg5 INHIBITING ANTICANCER AGENTS<br/>[FR] AGENTS ANTICANCÉREUX INHIBANT LA KINÉSINE MITOTIQUE EG5
  申请人：CLEVELAND CLINIC FOUNDATION

  公开号：WO2015153967A1

  公开（公告）日：2015-10-08

  A method of treating glioblastoma multiforme (GBM) in a subject in need thereof including administering to the subject a therapeutically effective amount of an Eg5 inhibitor.